<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IBANDRONATE SODIUM</span><br/><span class="topboxtradename">Boniva<br/></span><b>Classifications:</b> <span class="classification">bisphosphonate</span>; <span class="classification">regulator, bone metabolism</span><br/><b>Prototype: </b>Etidronate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg and 150 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Ibandronate inhibits activity of osteoclasts and reduces bone resorption and turnover in the matrix of the bone.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In postmenopausal women, it reduces the rate of bone turnover, resulting in a net gain in bone mass.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention and treatment of osteoporosis in postmenopausal women.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of metastatic bone disease in breast cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ibandronate; severe renal impairment; hypocalcemia; inability to stand or sit up straight for 60 min;
         concurrent administration with antacids, supplements, or vitamins; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Mild or moderate renal impairment; history of GI bleeding, esophagitis, esophageal, or gastric ulcers; pregnancy (category
         C), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Postmenopausal Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg qd or 150 mg once monthly on the same day each month<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cr<sub>Cl</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>	Correct hypocalcemia before administering ibandronate.</li>
<li>	Give at least 60 min before food, beverage, or other medications (including vitamins).</li>
<li>	Instruct to swallowed whole with a full glass of plain water (180240 mL; 68 oz) while standing or sitting in
            an upright position. 
         </li>
<li>	Keep patient sitting up or ambulating for 60 min after taking drug.</li>
<li>	Store between 15° and 30° C (59° and 86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, headache, nerve root lesion, vertigo.  <span class="typehead">GI:</span> Dyspepsia, constipation, diarrhea, esophagitis, gastritis, pharyngitis, nausea, vomiting. <span class="typehead">Respiratory:</span> Upper respiratory infection, pharyngitis. <span class="typehead">Skin:</span> Rash. <span class="typehead">Body as a Whole:</span> Back pain. <span class="typehead">Other:</span> Tooth disorder. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Interferes with the use of bone-imaging agents.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concurrent administration of <b>calcium,</b>
<b>magnesium,</b> or <b>iron</b> reduces ibandronate adsorption. <span class="typehead">Food:</span> Food reduces ibandronate absorption (ibandronate should be taken in a fasting state). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Bioavailability poor (0.6%). <span class="typehead">Peak:</span> 0.52 h. <span class="typehead">Distribution:</span> 8699% protein bound. <span class="typehead">Metabolism:</span> None. <span class="typehead">Elimination:</span> Renal. <span class="typehead">Half-Life:</span> 1060 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects </span></p>
<ul>
<li>	Lab tests: Monitor albumin-adjusted serum calcium, serum phosphate, serum alkaline phosphatase, fasting and 24 h urinary
            calcium, and serum electrolytes; baseline and periodic renal function. 
         </li>
<li>	Withhold drug and notify physician if the Cl<sub>cr</sub>
</li><li>	Diagnostic test: Bone density scan every 1218 mo.</li>
<li>	Monitor for S&amp;S of upper GI distress, especially with concurrent use of NSAIDS or aspirin.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>	Take the monthly dose (150 mg) on the same day each month. Carefully follow directions for taking the drug (see Administration).</li>
<li>	If a monthly dose is missed, and the next scheduled dose is more than 7 d away, take one 150 mg tablet the next morning then
            resume the original monthly schedule. Do not take two 150 mg tablets in the same week.
         </li>
<li>	Report to physician any of the following: severe bone, joint, or muscle pain; heartburn, pain behind the sternum, difficulty
            or pain with swallowing.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>